Administrative Core

管理核心：项目总结/摘要 哥伦比亚大学的使命乔治M。奥布莱恩泌尿科合作研究中心是 促进对良性泌尿生殖系统疾病/紊乱的了解。该中心由一个 行政（管理）核心，微生物基因组学生物医学研究核心，和三个研究 包括临床前和临床研究的项目。我们的关注点包括：（1）主持人的交集 基因组和尿微生物组;（2）在尿细胞分化过程中尿路上皮分化的转录调控 内稳态和修复响应UTI;和（3）如何调节尿化学和尿路上皮细胞 铁代谢（“铁-血红素机器”）是尿路上皮对UTI反应的组成部分。我们预计 拟议的研究将为与以下疾病高度相关的疾病的发病机制提供新的见解： 良性泌尿科，也有利于基因检测引入泌尿科的实践，甚至 提出了新的治疗方法我们将研究宿主和入侵细菌之间的相互作用， 营养铁在形成UT感染结果中的作用;我们将进行一项新的GWAS分析， 寻找导致LUTD的突变，包括失禁、梗阻和盆底脱垂，我们 将分析下尿路功能障碍（LUTD）患者的尿液微生物组，我们建议 确定可用于治疗良性尿路上皮疾病的尿路上皮细胞类型的途径， 与疾病有关的异常。该中心最重要的目标是利用专业知识， 泌尿外科界的经验，以增加我们的研究范围，并帮助指导各种 我们将解决的问题。我们直接整合了P20/U 54社区的成员， 良性泌尿外科领域的临床医生和科学家。我们项目的合作研究者包括英迪拉 泌尿道感染和尿路上皮生物学方面的专家，他将与门德尔松博士和约翰博士一起工作。 Barasch，Chad Vezina（威斯康星州U 54）和来自良性肿瘤的合作科学家和临床医生 泌尿外科社区，（洛里伯德，格里阿波达卡，道格斯特兰德）。此外，我们还邀请了 我们邀请一些专家加入我们的工作，例如血红素生物学家伊克巴尔·哈姆扎（马里兰州大学）。我们 也高度重视教育和推广：我们的暑期课程已经培训了73名学生，因为我们的 中心已成立，包括本科生，四年级医学生和泌尿外科 居民我们已经提供了机会池基金博士Putonti（洛约拉大学）和博士凯瑟琳 Brownstein，（哈佛大学）。我们在2019年10月举办了一次研讨会，非常成功 “UTI的问题：泌尿生殖道的微生物组及其免疫防御”汇集在一起 12位专家和超过138名泌尿外科社区成员。

ADMINISTRATIVE CORE: PROJECT SUMMARY/ABSTRACT The mission of the Columbia University George M. O’Brien Urology Cooperative Research Center is to advance the understanding of benign genitourinary diseases/disorders. The Center consists of an Administrative (Admin) Core, a Microbial Genomics Biomedical Research Core, and three Research Projects that include preclinical and clinical studies. Our focus includes: (1) the intersection of the host genome and the urinary microbiome; (2) the transcriptional regulation of urothelial differentiation during homeostasis and repair in response to UTI; and (3) how the regulation of urinary chemistry and urothelial iron metabolism (“iron-heme machine”) is a component of the urothelial response to UTI. We anticipate that the proposed studies will provide new insight into the pathogenesis of disorders of high relevance to benign urology and also facilitate introduction of genetic testing into the practice of Urology and even suggest new treatments. We will examine the interactions between host and invading bacteria, and the role of nutrient iron in shaping the outcome of UT infections; we will undertake a new GWAS analysis to search for mutations that lead to LUTD, including incontinence, obstruction and pelvic floor prolapse, we will analyze the urinary microbiome of patients with lower urinary tract disfunction (LUTD), and we propose to identify pathways that program urothelial cell types that may be used to treat benign urothelial abnormalities associated with disease. The most important goal of this center is to utilize the expertise and experience of the urological community to increase the scope of our studies and to help direct the kinds of questions we will address. We have directly integrated members of the P20/U54 community as well as clinicians and scientists in the benign urological community. Co-investigators on our projects include Indira Mysorekar (P20), an expert in UTI and urothelial biology who will work with Dr. Mendelsohn and Dr. Barasch, Chad Vezina (Wisconsin U54) and collaborating scientists and clinicians from the benign urological community, (Lori Birder, Gerry Apodaca, Doug Strand). In addition, we have invited outside experts to join our work, for example, the heme biologist, Iqbal Hamza (University of Maryland). We are also highly focused on education and outreach: Our summer program has trained 73 students since our center has been established, including undergraduates, fourth year medical students and urology residents. we have provided opportunity pool funds to Dr. Putonti (Loyola University) and Dr. Catherine Brownstein, (Harvard University). We held a Symposium in October of 2019 that was extremely successful "The problem of UTI: The microbiome of the Urogenital Tract and its immune Defense" bringing together a dozen experts with >138 members of the Urological community.